Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Bridgebio pharma, inc. save search
BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 0.29%
H: 3.53%
C: 1.42%
pharma approval study
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published: 2022-08-10 (Crawled : 12:00) - globenewswire.com
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 3.97%
H: 5.9%
C: 3.99%
nulibry treatment pharma israel approval therapeutics
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China
Published: 2021-12-21 (Crawled : 13:30) - biospace.com/
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 6.24%
H: 0.13%
C: -6.63%
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 0.07%
H: 4.03%
C: 2.15%
treatment china
Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Published: 2021-09-29 (Crawled : 14:00) - biospace.com/
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 0.38%
H: 1.15%
C: -5.31%
approval pharma
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 0.47%
H: 1.06%
C: -1.02%
treatment fda fda fast track fast track therapy fast track designation designation
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Published: 2021-05-28 (Crawled : 19:00) - globenewswire.com
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
fda fda approval approval pharma
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Published: 2021-02-28 (Crawled : 13:03) - globenewswire.com
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
fda risk fda approval therapy approval
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.
Published: 2021-01-19 (Crawled : 21:03) - globenewswire.com
BBIO | $24.95 -0.12% 0.0% 2.2M
|
Health Technology
|
| O: 0.22%
H: 2.69%
C: -2.62%
acquisition pharma
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.